CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-10 | Calvin Sandra SVP, Chief Accounting Officer | Sale | −436 | $21.51 | $9K | 36,178 |
| 2022-02-10 | Dube Eric M Chief Executive Officer | Sale | −4,832 | $27.84 | $135K | 159,913 |
| 2022-01-31 | Calvin Sandra VP, Corp Controller and CAO | Grant or award | +8,750 | 37,412 | ||
| 2022-01-31 | Calvin Sandra VP, Corp Controller and CAO | Sale | −798 | $26.51 | $21K | 36,614 |
| 2022-01-31 | Calvin Sandra VP, Corp Controller and CAO | Grant or award · Employee stock option (right to buy) | +17,500 | 17,500 | ||
| 2022-01-31 | Inrig Jula Chief Medical Officer | Grant or award · Performance-based restricted stock units | +8,000 | 8,000 | ||
| 2022-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +9,840 | 45,138 | ||
| 2022-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −1,350 | $27.40 | $37K | 43,788 |
| 2022-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Employee stock option (right to buy) | +39,360 | 39,360 | ||
| 2022-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Performance-based restricted stock units | +9,840 | 9,840 | ||
| 2022-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award · Performance-based restricted stock units | +8,000 | 8,000 | ||
| 2022-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +9,840 | 46,360 | ||
| 2022-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −1,125 | $27.40 | $31K | 45,235 |
| 2022-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Employee stock option (right to buy) | +39,360 | 39,360 | ||
| 2022-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Performance-based restricted stock units | +9,840 | 9,840 | ||
| 2022-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award · Performance-based restricted stock units | +8,000 | 8,000 | ||
| 2022-01-31 | Heerma Peter Chief Commercial Officer | Grant or award | +9,840 | 68,422 | ||
| 2022-01-31 | Heerma Peter Chief Commercial Officer | Sale | −1,125 | $27.40 | $31K | 67,297 |
| 2022-01-31 | Heerma Peter Chief Commercial Officer | Grant or award · Employee stock option (right to buy) | +39,360 | 39,360 | ||
| 2022-01-31 | Heerma Peter Chief Commercial Officer | Grant or award · Performance-based restricted stock units | +9,840 | 9,840 |
Page 31 of 51 · 1,020 trades